Abstract:Abstract Background On a worldwide basis, the prevalence of hepatocellular carcinoma (HCC) is twice as much in the past two decades, which is the third most common cause in cancer deaths. Therefore there is still an urgent need for new drugs with greater validity against HCC. Autophagy, which is essential in the intracellular clearance of many proteins and organelles, has been closely related to cancer generation and development. Generally, p53 is recognized as a pro-autophagic factor in a transcription-dependent pattern and also an important factor in the progress of HCC. As a selective substrate for autophagy, p62 is a key factor in tumorigenesis on account of its crucial roles in the control of cellular events. Now that small molecule compound-0404 was defined as a DNA-damaging reagent by the p53 pathway, our work aims to examine whether 0404 can affect p53-dependent autophagy and its positive effect in the treatment of HCC. Methods The anti-cancer activity of 0404 was examined in vitro. In the HepG2 cells and Huh7 cells, the apoptosis was detected by Flow Cytometry, while cell viability was measured by the CCK8 Assay. The Hela eGFP-LC3 cells, which express fusion protein combined light chain 3 (LC3) with enhanced Green Fluorescent Protein (eGFP), were treated with 0404 at various concentrations for various time points. HepG2 cells were treated with 0404 at various concentrations (5.0 nM, 20 nM, and 50 nM) for 24h. Autophagy was identified by eGFP-labeled LC3. And the expression levels of autophagy-associated proteins, such as mammalian target of rapamycin (mTOR), phospho-mTOR (p-mTOR), p62 and LC3B, were tested by Western Blotting. Results We confirmed that 0404 could inhibit the proliferation of HepG2 and Huh7 in a dose-dependent manner, and compared to Huh7 cells with mutant p53, HepG2 cells with wild-type p53 were more sensitive to 0404 treatment for apoptosis. We also found that 0404 promoted the development of autophagy in a dose- and time-dependent manner. Compared with untreated group, LC3 in 0404-treated groups resided primarily in the cytoplasm including cytoplasmic puncta indicative of autophagosomes. Simultaneously, the expression levels of mTOR and p62 were down-regulation, while the LC3B expression level was up-regulation by 0404-treatment. And the expression level of p-mTOR was down-regulation in a dose-dependent in HepG2 cells. Conclusion These results show clearly that DNA-damaging reagent-0404 can effectively inhibit HCC through p53-dependent autophagy. Acknowledgment This work was supported by the National Natural Science Foundation of China (81272679) and the Major national S&T Projects (2013ZX09041003). Citation Format: Min Zheng, Bingjue Ye, Guohua Lou, Caixia Xia, Weiyang Zheng, Yanning Yanning, Xiao Xu, Yongchao Zhao, Long Mao, Wanghong Xu. DNA-damaging reagent -0404 effectively inhibits hepatocellular carcinoma through p53-dependent autophagy. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3546.

Au-24 as a potential thioredoxin reductase inhibitor in hepatocellular carcinoma cells

The Au Clusters Induce Tumor Cell Apoptosis Via Specifically Targeting Thioredoxin Reductase 1 (trxr1) and Suppressing Its Activity

Synthesis and Molecular Recognition Studies on Small-Molecule Inhibitors for Thioredoxin Reductase

TR4 Nuclear Receptor Enhances the Cisplatin Chemo-Sensitivity Via Altering the ATF3 Expression to Better Suppress HCC Cell Growth

The Natural Diterpenoid Isoforretin A Inhibits Thioredoxin-1 and Triggers Potent ROS-Mediated Antitumor Effects.

Abstract 3546: DNA-damaging Reagent -0404 Effectively Inhibits Hepatocellular Carcinoma Through P53-Dependent Autophagy

In Vivo and in Vitro Suppression of Hepatocellular Carcinoma by EF24, a Curcumin Analog

TR4 Nuclear Receptor Suppresses HCC Cell Invasion Via Downregulating the EphA2 Expression

The Aryl Hydrocarbon Receptor Ligand ITE Inhibits Cell Proliferation and Migration and Enhances Sensitivity to Drug-Resistance in Hepatocellular Carcinoma.

A Derivative of Piperlongumine and Ligustrazine as a Potential Thioredoxin Reductase Inhibitor in Drug-Resistant Hepatocellular Carcinoma

Anti-tumor and Anti-Metastatic Effects of RRx-001 on Hepatocellular Carcinoma: Mechanisms of Action and Therapeutic Potential

Cyclin-Dependent Kinase 9 Inhibition As a Potential Treatment for Hepatocellular Carcinoma

Unveiling the cytotoxicity of a new gold(I) complex towards hepatocellular carcinoma by inhibiting TrxR activity

Potent Inhibition of Gastric Cancer Cells by a Natural Compound Via Inhibiting TrxR1 Activity and Activating ROS-mediated P38 MAPK Pathway

Pharmacological characterization of a novel metal-based proteasome inhibitor Na-AuPT for cancer treatment

A novel AKR1C3 specific prodrug AST-3424 and its combination therapy in hepatocellular carcinoma

Redox Status of Thioredoxin-1 (TRX1) Determines the Sensitivity of Human Liver Carcinoma Cells (hepg2) to Arsenic Trioxide-Induced Cell Death

Thiostrepton as a Potential Therapeutic Agent for Hepatocellular Carcinoma

Role of Thioredoxin Reductase 1 in Multidrug Resistance Caused by Reactive Oxygen Species-Related Cell Apoptosis in Hepatocellular Carcinoma

Diffractaic acid exerts anti-cancer effects on hepatocellular carcinoma HepG2 cells by inducing apoptosis and suppressing migration through targeting thioredoxin reductase 1

Diphenyl Difluoroketone: A Potent Chemotherapy Candidate For Human Hepatocellular Carcinoma